Cathay Biotech Full Year 2023 Earnings: Misses Expectations

Cathay Biotech (SHSE:688065) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥2.11b (down 13% from FY 2022).
• Net income: CN¥366.5m (down 34% from FY 2022).
• Profit margin: 17% (down from 23% in FY 2022). The decrease in margin was driven by lower revenue.
• EPS: CN¥0.63 (down from CN¥0.95 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cathay Biotech Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 34%.

The company's shares are up 27% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for Cathay Biotech that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.